Glipizide and metformin and Linagliptin interaction

Glipizide and metformin and Linagliptin: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Glipizide and metformin (Glipizide and Metformin Hydrochloride) label · effective 2026-06-27

Major

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.

Contraindicationsby drug classView label on DailyMed
Moderate

The risk of hypoglycemia is increased when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents or ethanol.

Precautionsby drug classView label on DailyMed
Moderate

Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with glipizide and metformin hydrochloride or any other antidiabetic drug.

Precautionsby drug classView label on DailyMed
Moderate

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.

Precautionsby drug classView label on DailyMed

From the Linagliptin (Tradjenta) label · effective 2025-03-21

Moderate

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 )

Warnings and precautionsby drug classView label on DailyMed
Moderate

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues Insulin secretagogues and insulin are known to cause hypoglycemia.

Warnings and precautionsby drug classView label on DailyMed
Moderate

The risk of hypoglycemia is increased when TRADJENTA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin [see Adverse Reactions (6.1) ] .

Warnings and precautionsby drug classView label on DailyMed
Moderate

Therefore, a lower dosage of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with TRADJENTA.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.